Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Medical Case Reports|September 29, 2020
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case reportThachanun Porntharukchareon, Borwonkhun Tontivuthikul, Nattaya Sintawichai, et al.
AACE Clinical Case Reports|May 23, 2022
Desmopressin Stimulation Test in a Pregnant Patient with Cushing's DiseaseWasita Warachit Parksook, Thachanun Porntharukchareon, Sarat Sunthornyothin
Frontiers in Endocrinology|July 18, 2024
The existence of adrenal insufficiency in patients with COVID-19 pneumoniaThachanun Porntharukchareon, Bothamai Dechates, Supamas Sirisreetreerux, et al.
Diabetology International|May 9, 2022
Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccineVimonsri Rangsrisaeneepitak, Thachanun Porntharukchareon, Bothamai Dechates, et al.
Expert Review of Vaccines|July 6, 2022
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccineKriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, et al.
Human Vaccines & Immunotherapeutics|March 4, 2022
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai populationKriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, et al.
Vaccines|March 30, 2023
Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare WorkersBothamai Dechates, Thachanun Porntharukchareon, Supamas Sirisreetreerux, et al.
Scientific Reports|July 21, 2023
Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai populationSupamas Sirisreetreerux, Thachanun Porntharukchareon, Bothamai Dechates, et al.
Vaccine|February 25, 2022
Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trialKriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, et al.
Human Vaccines & Immunotherapeutics|May 4, 2023
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental studyKriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, et al.
Pageof 2